Valentina Veronesi

Valentina Veronesi

Auto-generated profile, based on publicly available information

Valentina Veronesi

Multimedica

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2022 in Computers & Education
Verified
Journal Article
Closed access
ARAngelica Ronconi
Angelica Ronconi
VVValentina Veronesi
Valentina Veronesi
LMLucia Mason
Lucia Mason
LMLucia Manzione
Lucia Manzione
EFElena Florit
Elena Florit
IBIvar Bråten
Ivar Bråten

8 September 2023 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
PLPietro Maria Lombardi
Pietro Maria Lombardi
MMMichele Mazzola
Michele Mazzola
VVValentina Veronesi
Valentina Veronesi
SGStefano Granieri
Stefano Granieri
SCStefano Piero Bernardo Cioffi
Stefano Piero Bernardo Cioffi
GFGiovanni Ferrari
Giovanni Ferrari

2 February 2022 in Colorectal Disease
Verified
Journal Article
Closed access
PDF file
AGAlessandro Giani
Alessandro Giani
VVValentina Veronesi
Valentina Veronesi
CBCamillo Leonardo Bertoglio
Camillo Leonardo Bertoglio
MMMichele Mazzola
Michele Mazzola
DBDavide Paolo Bernasconi
Davide Paolo Bernasconi
GFGiovanni Ferrari
Giovanni Ferrari

21 February 2023 in HPB
Verified
Journal Article
Closed access
MMMichele Mazzola
Michele Mazzola
AGAlessandro Giani
Alessandro Giani
VVValentina Veronesi
Valentina Veronesi
DBDavide P. Bernasconi
Davide P. Bernasconi
ABAntonio Benedetti
Antonio Benedetti
GFGiovanni Ferrari
Giovanni Ferrari

19 February 2024 in Clinical Oral Implants Research
Verified
Journal Article
Open access
Mattia ManfrediniMattia Manfredini
Mattia Manfredini
Pier Paolo PoliPier Paolo Poli
Pier Paolo Poli
MBMario Beretta
Mario Beretta
FRFederico Rossi
Federico Rossi
MRMarta Rigoni
Marta Rigoni
CMCarlo Maiorana
Carlo Maiorana
Objectives: The effect of the implant position within the prosthesis on bone remodeling is scarcely documented so far. Thus, the aim of the present study was to investigate whether central implants may suffer higher peri‐implant marginal bone levels (MBL) compared to laterals in case of fixed splinted bridges supported by ≥ three implants.Materials and Methods: Partially edentulous subjects rehabilitated with at least one fixed bridge supported by ≥ three dental implants were enrolled. MBL was assessed radiographically by means of intraoral radiographs acquired with phosphor plates and imported in a dedicated software. MBL was calculated as the distance between the implant platform level and the most coronal visible bone‐to‐implant contact. A three‐level linear mixed effects model was used for investigating the fixed effect of patient‐, prosthesis‐, and implant‐level variables on the MBL.Results: Overall, 90 patients rehabilitated with 130 splinted fixed bridges supported by 412 implants were included. The median follow‐up was 136 months. The mean peri‐implant MBL resulted statistically significantly higher at central implants if compared to lateral implants (p < .01). The estimated MBL averages for central and external implants were 1.68 and 1.18 mm, respectively. The prosthesis‐level variables suggested that a cement‐retained bridge was prone to a significant 0.82 mm higher MBL than a screw‐retained one. Implant surface showed an association with MBL changes, although less pronounced than implant retention.Conclusions: In case of ≥3 adjacent implants supporting splinted bridges, central implants were more predisposed to MBL compared to laterals. At the prosthesis level, implants supporting cement‐retained bridges were statistically more susceptible to MBL compared to screw‐retained ones. Surface characteristics can also influence MBL stability at the implant level.

12 December 2024 in Cancers
Verified
Journal Article
Open access
PDF file
DGDonatella Gambini
Donatella Gambini
VVValentina Veronesi
Valentina Veronesi
LDLuca Despini
Luca Despini
SFStefano Ferrero
Stefano Ferrero
CRClaudia Rossi
Claudia Rossi
EKElisabetta Kuhn
Elisabetta Kuhn
Background: The lengthening of the lifespan led to an increase in breast cancer (BC) diagnosed in very old age, but the treatment recommendations in this patient group usually lack evidence-based practice. We conducted a prospective observational monocentric study specifically targeting patients diagnosed with invasive BC at 80 years of age or older. Methods: We enrolled 88 patients consecutively observed for a new BC diagnosis at 80 years or older. The aim was to investigate progression-free (PFS) and overall survival (OS), with a long follow-up period, along with clinico-pathological characteristics of the population. Results: At the end of the 5-year follow-up, the estimated OS and PFS probabilities were 82.9% (95% CI: 71.3–95.3%) and 64.0% (95% CI: 51.7–79.2%), respectively. After 8.5 years from the BC diagnosis, 48.9% died. The cause of death was BC in 32.6% of patients, different from BC in 13.9%, and unknown in the remaining. Surgery was performed in 69.3% of the cases and was associated with improved 12-month PFS (p < 0.001). Adjuvant systemic therapy and radiotherapy were omitted in 32% and 93% of eligible patients, respectively. A higher rate of metastatic disease at the diagnosis was observed in comparison with data described in younger people, as well as a significantly high rate of drop-out (27.3%). Conclusions: Ultra-old patients have a not negligible life expectancy; therefore, the oncologic treatment should be optimal and should adequately fight BC, always considering the quality of life of these frail patients. Future research should focus on developing personalized treatment protocols that incorporate comprehensive geriatric assessments and quality-of-life metrics. Additionally, larger, multicentric studies are needed to validate our findings and explore the role of emerging therapies in this age group.